AHA/ACC — Hypertrophic cardiomyopathy

Wall ≥15 mm (≥13 mm with family history). Mavacamten/aficamten for obstructive HCM with LVOT gradient monitoring.

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy. Circulation. 2024;149(23):e1239-e1311.

Read the full guideline (official text)

Used in: LV tab notes